Trusted Resource for Clinical Trials, Protocols & Progress
Even though Phase 0 trials involve microdoses and no therapeutic intent, they are still clinical trials involving human participants. This means they must adhere to the highest ethical and safety standards. The fact that Phase 0 studies may offer no direct benefit to the subject makes ethical oversight even more critical.
Click to read the full article.
Phase 0 trials, although short and low-risk, are still governed by regulatory frameworks. Before starting human studies, sponsors must obtain authorization from national health authorities. This ensures that human subjects are protected and the study is scientifically and ethically justified.
Click to read the full article.
In Phase 0 trials, drug doses are so small that plasma concentrations are often in the picogram to nanogram range. This means standard analytical methods may not be sensitive enough to detect them. Therefore, the success of any microdosing study hinges on developing highly sensitive, specific, and validated bioanalytical assays.
Click to read the full article.
The main objective of most Phase 0 trials is to gather pharmacokinetic (PK) data in humans using microdose levels. These early insights help answer crucial questions such as: Is the drug absorbed? How long does it stay in circulation? Does it behave as expected?
Click to read the full article.
While Phase 0 studies are shorter and involve fewer participants than traditional trials, their setup requires meticulous planning and coordination. These trials often involve advanced technologies like microdosing, ultra-sensitive bioanalysis, and imaging endpoints, so having the right team, infrastructure, and subject management strategy is critical for success.
Click to read the full article.
Drug development is time-consuming and resource-intensive. Making informed go/no-go decisions as early as possible can prevent costly failures later. Phase 0 trials, through microdosing and focused pharmacokinetic/pharmacodynamic (PK/PD) evaluations, provide real-world human data to evaluate whether a drug candidate is worth advancing to Phase 1 and beyond.
Click to read the full article.
Phase 0 trials—or exploratory microdosing studies—may be low-risk, but they are still subject to stringent regulatory oversight. Each country has unique pathways for approval, risk classification, and ethical review. Understanding how agencies like the FDA (U.S.), EMA (Europe), CDSCO (India), and PMDA (Japan) approach Phase 0 trials is essential for global drug development planning.
Click to read the full article.
Phase 0 trials offer real human PK data at microdose levels—but alone, they can’t predict full-dose behavior for every compound. To bridge this gap, researchers increasingly rely on in silico modeling and physiologically based pharmacokinetic (PBPK) simulations. These computational approaches improve dose predictions, inform study design, and support go/no-go decisions—especially when clinical data is sparse.
Click to read the full article.
Although Phase 0 trials involve human subjects and follow GCP, they also rely heavily on nonclinical data, analytical labs, and sample handling—all of which fall under Good Laboratory Practice (GLP) principles. Writing clear, consistent, and compliant protocols and SOPs ensures data integrity, regulatory acceptability, and operational efficiency throughout the microdosing study.
Click to read the full article.
Phase 0 trials are small, fast, and cost-effective—but they must be carefully designed to yield meaningful data. Because these microdosing studies are non-therapeutic, researchers sometimes underestimate their complexity. Design missteps can compromise data quality, delay development, or even invalidate the study. This article highlights the most common pitfalls and offers practical ways to avoid them.
Click to read the full article.
